Additionally, potent anti-proliferative activity has been observed with a number of BET inhibitors in models of hematologic cancer, including acute myeloid leukemia [16,17], MLL-fusion leukemias [11], Burkitt’s lymphoma [17], multiple myeloma [18], and B-cell acute lymphoblastic leukemia [19]. The gene discussed is KMT2A; the disease is leukemia.